Are Cancer Drugs Worth the Money? MSKCC Tool Tests Pricing Rationale

A health services researcher at Memorial Sloan-Kettering Cancer Center has proposed a method for assessing whether cancer drugs are rationally priced.

House Spending Bill to Eliminate AHRQ While Adding $1.1 Billion to NIH Budget

By Nick Crispino and Matthew Bin Han Ong

Free

AAUP Places MD Anderson on Censure List

By Matthew Bin Han Ong

Congress Reintroduces Bill to Limit Out-of-Pocket Costs for Oral Anticancer Drugs

By Nick Crispino

CPRIT Reaches Milestone in Providing 2 Million Cancer Prevention Services to Texans

Recent Issues

Volume 50 | Issue 46 - December 13, 2024

Are Cancer Drugs Worth the Money? MSKCC Tool Tests Pricing Rationale

House Spending Bill to Eliminate AHRQ While Adding $1.1 Billion to NIH Budget

AAUP Places MD Anderson on Censure List

Congress Reintroduces Bill to Limit Out-of-Pocket Costs for Oral Anticancer Drugs

CPRIT Reaches Milestone in Providing 2 Million Cancer Prevention Services to Texans

In Brief

Sampson Named Chair of Duke Department of Neurosurgery

John Zaia named director of City of Hope’s Center for Gene Therapy

AHRQ to fund three centers of excellence with $52 million over five years

Eli Lilly & Co. announces collaborations with Dana-Farber and Sarah Cannon Research Institute

Drugs & Targets

European Commission Grants Authorization to Gardasil 9

FDA approves Ventana ALK (D5F3) CDx companion diagnostic assay for Xalkori

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login